Cargando…

Reactivation of Human Herpesvirus-6 in Natalizumab Treated Multiple Sclerosis Patients

The α(4) integrin antagonist natalizumab was shown to be effective in patients with immune-mediated disorders but was unexpectedly associated with JC polyomavirus associated progressive multifocal leukoencephalopathy (PML) in two multiple sclerosis (MS) and one Crohn's disease patients. Impaire...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Karen, Gagnon, Susan, Akhyani, Nahid, Williams, Elizabeth, Fotheringham, Julie, Frohman, Elliot, Stuve, Olaf, Monson, Nancy, Racke, Michael K., Jacobson, Steven
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2008
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2323568/ https://www.ncbi.nlm.nih.gov/pubmed/18446218 http://dx.doi.org/10.1371/journal.pone.0002028

Ejemplares similares

Differential tropism of human herpesvirus 6 (HHV-6) variants and induction of latency by HHV-6A in oligodendrocytes
por: Ahlqvist, Jenny, et al.
Publicado: (2005)

Pain in Multiple Sclerosis: Understanding Pathophysiology, Diagnosis, and Management Through Clinical Vignettes
por: Racke, Michael K., et al.
Publicado: (2022)

Association of Human Herpesvirus-6B with Mesial Temporal Lobe Epilepsy
por: Fotheringham, Julie, et al.
Publicado: (2007)

Natalizumab wearing-off effect: The hunt for the elusive pharmacodynamic biomarker
por: Foley, John F., et al.
Publicado: (2020)

Cerebellar syndrome in a man treated with natalizumab: From the National Multiple Sclerosis Society Case Conference Proceedings
por: Lapides, David A., et al.
Publicado: (2019)

The genetics of natalizumab hypersensitivity: One learns to itch where one can scratch
por: Stüve, Olaf, et al.
Publicado: (2014)

Changes in JC Virus-Specific T Cell Responses during Natalizumab Treatment and in Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
por: Perkins, Molly R., et al.
Publicado: (2012)

Neuron-binding antibody responses are associated with Black ethnicity in multiple sclerosis during natalizumab treatment
por: Telesford, Kiel M, et al.
Publicado: (2023)

Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation
por: Iannetta, Marco, et al.
Publicado: (2016)

The sequential natalizumab – alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial – Part I: Rationale and objectives
por: Hussain, Rehana Z, et al.
Publicado: (2022)

Glioblastoma in natalizumab‐treated multiple sclerosis patients
por: Sierra Morales, Fabian, et al.
Publicado: (2017)

Multiple Sclerosis Followed by Neuromyelitis Optica Spectrum Disorder: From the National Multiple Sclerosis Society Case Conference Proceedings
por: Goldschmidt, Carolyn, et al.
Publicado: (2022)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Natalizumab in the treatment of multiple sclerosis
por: Brown, Brandon A
Publicado: (2009)

The use of natalizumab for multiple sclerosis
por: Brandstadter, Rachel, et al.
Publicado: (2017)

Natalizumab Rebound in Multiple Sclerosis
por: Lee, Joshua D., et al.
Publicado: (2021)

Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis
por: Prosperini, Luca, et al.
Publicado: (2019)

Cognitive evolution in natalizumab-treated multiple sclerosis patients
por: Jacques, Francois H, et al.
Publicado: (2016)

Natalizumab for the treatment of relapsing multiple sclerosis
por: Rudick, Richard A, et al.
Publicado: (2008)

PEG Minocycline-Liposomes Ameliorate CNS Autoimmune Disease
por: Hu, Wei, et al.
Publicado: (2009)

Clinical Immunological Correlations in Patients with Multiple Sclerosis Treated with Natalizumab
por: Maier, Smaranda, et al.
Publicado: (2020)

Natalizumab in Multiple Sclerosis: Long-Term Management
por: Clerico, Marinella, et al.
Publicado: (2017)

Recurrent Optic Neuritis and Perineuritis Followed by an Unexpected Discovery: From the National Multiple Sclerosis Society Case Conference Proceedings
por: Pimentel Maldonado, Daniela A., et al.
Publicado: (2022)

Dynamic changes of MMP-9 plasma levels correlate with JCV reactivation and immune activation in natalizumab-treated multiple sclerosis patients
por: Iannetta, Marco, et al.
Publicado: (2019)

Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment
por: Tur, Carmen, et al.
Publicado: (2013)

The discovery of natalizumab, a potent therapeutic for multiple sclerosis
por: Steinman, Lawrence
Publicado: (2012)

Comparative efficacy of switching to natalizumab in active multiple sclerosis
por: Spelman, Timothy, et al.
Publicado: (2015)

The role of natalizumab in the treatment of multiple sclerosis: benefits and risks
por: Singer, Barry A.
Publicado: (2017)

Relapse-independent multiple sclerosis progression under natalizumab
por: Graf, Jonas, et al.
Publicado: (2021)

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis
por: Callegari, Ilaria, et al.
Publicado: (2023)

Rituximab Therapy Reduces Organ-Specific T Cell Responses and Ameliorates Experimental Autoimmune Encephalomyelitis
por: Monson, Nancy L., et al.
Publicado: (2011)

Immunological and clinical consequences of splenectomy in a multiple sclerosis patient treated with natalizumab
por: Lee, De-Hyung, et al.
Publicado: (2013)

Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab
por: Dominguez-Mozo, Maria Inmaculada, et al.
Publicado: (2020)

Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
por: Fissolo, Nicolás, et al.
Publicado: (2021)

Natalizumab concentrations during pregnancy in three patients with multiple sclerosis: A clinical commentary
por: Dobson, Ruth, et al.
Publicado: (2022)

Spotlight on daclizumab: its potential in the treatment of multiple sclerosis
por: Milo, Ron, et al.
Publicado: (2016)

Natalizumab: A new treatment for relapsing remitting multiple sclerosis
por: Hutchinson, Michael
Publicado: (2007)

Clinical efficacy issues in the treatment of multiple sclerosis: update of natalizumab
por: Patti, Francesco, et al.
Publicado: (2009)

Unusual deterioration in a patient with multiple sclerosis on natalizumab therapy
por: Gattringer, Thomas, et al.
Publicado: (2014)

Effect of Natalizumab on Circulating CD4(+) T-Cells in Multiple Sclerosis
por: Börnsen, Lars, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_efeec0cue19ii1mu66g91mpqk0